Double immune attack: new cell combo targets tough childhood cancers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PROCUREMENT INCLUSION: 1. Patients with Neuroblastoma that have persistent disease after standard treatment or have relapsed/refractory disease. Or Patients with Osteosarcoma that have persistent disease after standard treatment or have relapsed/refractory disease. 2. Karnofsky/Lansky score of 60% or greater. 3. Informed consent and assent (as applicable) obtained from parent/guardian and child. 4. Greater than 1 year of age. PROCUREMENT EXCLUSION: 1. History of hypersensitivity to murine protein-containing products. 2. Known presence of Human Anti-Mouse Antibodies (HAMA). 3. Active autoimmune disease (requiring immunosuppressive treatment in the past 6 months). 4. Primary brain tumor or known brain metastases (on evaluation by MIBG and/or PET if applicable, CT/MRI/LP not required). TREATMENT INCLUSION: 1. Patients with Neuroblastoma that have persistent disease after standard treatment or have relapsed/refractory disease. Or Patients with Osteosarcoma that have persistent disease after standard treatment or have relapsed/refractory disease. 2. Karnofsky/Lansky score of 50% or greater 3. Pulse Ox greater than or equal to 90% on room air 4. AST less than 5 times upper limit of normal (less than 10 times upper normal if known with metastatic liver disease) 5. Total bilirubin less than 3 times the upper limit of normal 6. Serum creatinine less than 3 times upper limit of normal 7. Available autologous T-cells with greater than or equal to 20% expressing GD2.CAR 8. Informed consent and assent (as applicable) obtained from parent/guardian and child. 9. Greater than 1 year of age. 10. Recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study. TREATMENT EXCLUSION: 1. History of hypersensitivity to murine protein containing products (patients who have undergone desensitization and successful re-challenge without hypersensitivity reaction are eligible). 2. Known presence of Human Anti-Mouse Antibodies (HAMA). 3. Tumor potentially causing airway obstruction per investigator discretion. 4. Pregnancy or lactation / will not use birth control methods. 5. Currently receiving immunosuppressive drugs (patients on low dose corticosteroids are eligible: less than 0.25 mg/kg/day of prednisone/equivalent). 6. Primary brain tumor or known brain metastases (on evaluation by MIBG and/or PET if applicable, CT/MRI/LP not required).